Zacks Investment Research
06 Aug 2026, 14:51 UTC · 1h ago
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 14:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CG Oncology reported quarterly revenues of $1.16 million, missing the Zacks Consensus Estimate by 59.02%. — A significant revenue miss of nearly 60% typically indicates weaker-than-expected commercial traction or operational headwinds.
-0.60CG Oncology reported a quarterly loss of $0.90 per share, exceeding the estimated loss of $0.70 per share. — The earnings miss and widening loss compared to the previous year suggest increasing costs or inefficient burn rates.
-0.40CG Oncology has only surpassed consensus EPS estimates once over the last four quarters. — A consistent pattern of missing earnings estimates undermines investor confidence in management's guidance.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported a larger than expected quarterly loss and missed revenue estimates significantly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
56m ago
